Innate Pharma S.A.
NASDAQ:IPHABiotechnology
+$0.03 today
- Market cap
- $104.99M
- Beta
- 0.89
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.54
Volume 0.06M
Average 0.07M
IPHA Deferred Income Tax
The difference between tax expense recognized and tax actually paid in cash during the period.
Innate Pharma S.A.NASDAQ: IPHA
{ "id": "headlineOutflowGrows", "params": { "amount": { "type": "amount", "value": 0 } } }
[ { "id": "valueVsYearAgo", "params": { "period": { "type": "period", "period": { "kind": "quarter", "fiscalYear": 2025, "fiscalQuarter": 4 } }, "amount": { "type": "amount", "value": 0 }, "previous": { "type": "amount", "value": 0 } } } ]
Context
- { "id": "shareOfRevenueUnchanged", "params": { "share": { "type": "share", "value": 0 }, "period": { "type": "period", "period": { "kind": "fiscalYear", "fiscalYear": 2025 } } } }
- { "id": "streakIncreased", "params": { "rises": { "type": "count", "value": 0 }, "years": { "type": "count", "value": 3 } }, "count": 3 }
- { "id": "extremeHighestFigure", "params": { "fiscalYear": { "type": "fiscalYear", "value": 2025 }, "years": { "type": "count", "value": 4 } } }
Sources:Cash FlowText generated from reported figures; not investment advice.
Deferred Income Tax history
EUR · from the cash flow
- Latest · FY2025
- 0 EUR
- Year-over-year change
- —
| Period | Period end | Deferred Income Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (1.68M) | — |
Deferred Income Tax vs competitors
How IPHA compares with its peers on the latest reported figures
- { "id": "currencyMixedRevenue", "params": {} }
- { "id": "shareOfRevenueMedian", "params": { "ticker": { "type": "text", "value": "IPHA" }, "share": { "type": "share", "value": 0 }, "median": { "type": "share", "value": 0 } } }
| Company | Period | YoY | 3-year CAGR | |
|---|---|---|---|---|
| — | €0 EUR | — | — | |
| — | $0 USD | — | — | |
| — | $0 USD | — | — | |
| — | CHF 0 CHF | +100.0% | — | |
| — | $0 USD | — | — | |
| — | $0 USD | — | — | |
| — | $0 USD | — | — | |
| — | $0 USD | — | — | |
ELTXElicio Therapeutics, Inc. | — | $0 USD | -100.0% | — |
| Peer median (excluding IPHA) | — | +0.0% | — | |
Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (52.81M) | (58.1M) | (7.57M) | (49.47M) | (49.18M) |
| Depreciation & Amortization | 4.6M | 45.41M | 5.09M | 1.99M | 5.09M |
| Deferred Income Tax | (1.68M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.62M | 4.25M | 4.26M | 3.94M | 4.26M |
| Change in Working Capital | (9.88M) | (12.5M) | (32.09M) | 39.16M | (10.21M) |
| Accounts Receivables | 3.39M | (4.2M) | (13.67M) | 0 | 0 |
| Inventory | (6.27M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (946K) | (7.66M) | (3.89M) | 0 | 0 |
| Other Working Capital | (6.06M) | (636K) | (10.54M) | 39.16M | (10.21M) |
| Other Non-Cash Items | (1.3M) | 1.8M | (2.24M) | (2.53M) | (630.52K) |
| Operating Cash Flow | (58.46M) | (19.15M) | (32.56M) | (6.9M) | (50.67M) |
| Capital Expenditures | (1.33M) | (1.12M) | (2.35M) | (391K) | (134.47K) |
| Acquisitions (Net) | 7K | 0 | 0 | 0 | 4.8K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 3M | 22.77M | 9.59M | 13.51M |
| Other Investing Activities | 406K | (1K) | (1.79M) | 1K | (6.38M) |
| Investing Cash Flow | (917K) | 1.88M | 20.63M | 9.2M | 7M |
| Debt Repayment | 26.63M | (2.03M) | (2.36M) | (8.94M) | (8.56M) |
| Common Stock Issued | 499K | 198K | 395K | 2.93M | 14.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 187K | 198K | 395K | 2.93M | 0 |
| Financing Cash Flow | 26.82M | (1.83M) | (1.97M) | (6.01M) | 5.83M |
| Effect of Forex Changes | (483K) | (428K) | 274K | (505K) | 7.41M |
| Net Change in Cash | (33.04M) | (19.53M) | (13.62M) | (4.21M) | (30.44M) |
| Free Cash Flow | (59.79M) | (20.28M) | (34.91M) | (7.29M) | (50.81M) |
Innate Pharma S.A.
NASDAQ:IPHA
Intrinsic Alpha fair value
Locked
Current Price
$0.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.